Lp(a) FRONTIERS CAVS
99 years and younger
All genders
Requesting a reliance agreement with an external IRB. The purpose of this study is to assess if the study treatment, pelacarsen (TQJ230), taken by participants with mild or moderate calcific aortic valve stenosis (CAVS) and elevated lipoprotein(a) [Lp(a)] can safely help slow the progression of CAVS. Patients will be between …